CH0499880968 - Common Stock

Overall **ADCT** gets a fundamental rating of **2** out of 10. We evaluated **ADCT** against 610 industry peers in the **Biotechnology** industry. **ADCT** may be in some trouble as it scores bad on both profitability and health. **ADCT** does not seem to be growing, but still is valued expensively.

In the past year **ADCT** has reported negative net income.

In the past 5 years **ADCT** always reported negative net income.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -38.23% | ||

ROE | N/A | ||

ROIC | N/A |

ROA(3y)-38.2%

ROA(5y)-56.19%

ROE(3y)-129.18%

ROE(5y)-117.97%

ROIC(3y)N/A

ROIC(5y)N/A

With an excellent **Gross Margin** value of **98.36%**, **ADCT** belongs to the best of the industry, outperforming **98.01%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 98.36% |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

Compared to 1 year ago, **ADCT** has more shares outstanding

Compared to 5 years ago, **ADCT** has more shares outstanding

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | N/A | ||

Altman-Z | -3.05 |

ROIC/WACCN/A

WACC6.7%

A Current Ratio of **4.80** indicates that **ADCT** has no problem at all paying its short term obligations.

With a **Quick ratio** value of **4.51**, **ADCT** perfoms like the industry average, outperforming **48.51%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 4.8 | ||

Quick Ratio | 4.51 |

The Revenue for **ADCT** has decreased by **-21.99%** in the past year. This is quite bad

The **Revenue** has been growing by **159.03%** on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-1.85%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q10.77%

Revenue 1Y (TTM)-21.99%

Revenue growth 3Y350.22%

Revenue growth 5Y159.03%

Revenue growth Q2Q-81.01%

EPS Next Y-25.87%

EPS Next 2Y-2.17%

EPS Next 3Y5.67%

EPS Next 5YN/A

Revenue Next Year-65.48%

Revenue Next 2Y-35.87%

Revenue Next 3Y-21.12%

Revenue Next 5Y4.99%

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **ADCT**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-2.17%

EPS Next 3Y5.67%

No dividends for **ADCT**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**ADC THERAPEUTICS SA**

NYSE:ADCT (12/8/2023, 7:04:00 PM)

**1.02**

**-0.05 (-4.67%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap82.25M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -38.23% | ||

ROE | N/A | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 98.36% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.26

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 4.8 | ||

Quick Ratio | 4.51 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-1.85%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-25.87%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-21.99%

Revenue growth 3Y350.22%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y